Mehmet Kizilkaya | Cancer Biology | Innovative Research Award

Published on by Molecular Biologist

Innovative Research Award

Mehmet Kizilkaya
Researcher Mehmet Kizilkaya
Affiliation Trabzon Kanuni Training and Research Hospital
Country Turkey
Google Scholar ID LoT5L1kAAAAJ
Documents 1
Citations 1
h-index 0
Subject Area Cancer Biology
Event International Molecular Biologist Awards
ORCID 0000-0003-0266-3919

Mehmet Kizilkaya

Trabzon Kanuni Training and Research Hospital, Turkey

Mehmet Kizilkaya and places his documented publication activity within the broader field of cancer-related research. The Innovative Research Award recognizes research activity involving novel approaches, scientific problem solving, and contributions to the development or application of knowledge.[1][2]

Abstract

Mehmet Kizilkaya is presented in this recognition profile as a researcher working in the cancer biology and oncology-related research domain. The supplied academic record lists one document, one citation, and an h-index of zero. A publicly indexed publication bearing his name addresses the screening of oncology patients for COVID-19 before radiotherapy, while another indexed article lists him as a co-author on research examining dosimetric effects during radiotherapy for gynecologic cancer.[1][2]

Keywords

Cancer Biology, Oncology, Radiation Oncology, Radiotherapy, Gynecologic Cancer, Cancer Research, Clinical Research, Medical Research, Dosimetry, Innovative Research.

Introduction

Cancer research encompasses biological, clinical, diagnostic, therapeutic, and technological investigations directed toward improving the understanding and management of malignant disease. Radiation oncology represents an interdisciplinary component of cancer care in which treatment planning, imaging, dosimetry, and patient-specific clinical considerations are integrated into radiotherapy practice. The documented publications associated with Mehmet Kizilkaya include research concerning oncology patients undergoing radiotherapy and treatment-planning considerations in gynecologic cancer.[1][2]

Research Profile

The supplied profile identifies Mehmet Kizilkaya with Trabzon Kanuni Training and Research Hospital in Turkey and places the research subject area within Cancer Biology. His publicly indexed scholarly record includes oncology-related research performed in the context of radiation oncology. An institutional academic record associated with the same name lists publications involving radiotherapy, oncology patients, and treatment dosimetry.[1][2]

  • Research area supplied for this recognition profile: Cancer Biology.
  • Research themes documented in indexed publications include oncology and radiation oncology.
  • Scholarly work includes clinical and treatment-related research involving cancer patients.
  • Google Scholar profile identifier: LoT5L1kAAAAJ.

Research Contributions

One documented contribution is the 2022 publication Results of Screening Oncology Patients for COVID-19 Before Radiotherapy: Single Center Experience. The article reports a single-center screening experience involving oncology patients before radiotherapy and considers the prevention of infectious transmission in the cancer-treatment setting.[1]

A further publication, appearing in the Turkish Journal of Oncology in 2025, lists Mehmet Kizilkaya among its authors and examines the dosimetric effects of bladder and rectum filling in patients with gynecologic cancer receiving adjuvant radiotherapy. The study was published with DOI 10.5505/tjo.2024.4429.[2]

Publications

  • Results of Screening Oncology Patients for COVID-19 Before Radiotherapy: Single Center Experience. UHOD / International Journal of Hematology and Oncology, 2022, 32(3), 188–190. DOI: 10.4999/uhod.226389.[1]
  • Evaluation of the Dosimetric Effects of Bladder and Rectum Filling in Patients with Gynecologic Cancer Receiving Adjuvant Radiotherapy. Turkish Journal of Oncology, 2025, 40(1), 11–19. DOI: 10.5505/tjo.2024.4429.[2]

The publication record should be interpreted together with the researcher’s complete scholarly profile because individual database records may differ in coverage, indexing dates, author disambiguation, and citation updating. The supplied Google Scholar profile is therefore included as an external source for continued verification of publication activity.[3]

Research Impact

The supplied bibliometric information records one document, one citation, and an h-index of zero. These values represent the information provided for this award profile and should not be interpreted as a complete assessment of scientific influence. Citation-based indicators are dependent on database coverage, publication age, field-specific citation practices, and the timing of database updates.[3]

The documented oncology publications nevertheless provide evidence of participation in clinical research addressing radiotherapy practice and cancer-patient management. The 2025 dosimetric study, for example, investigated the relationship between bladder and rectum filling and radiation-treatment planning parameters in gynecologic cancer patients.[2]

Award Suitability

The Innovative Research Award profile is based on documented research participation, subject relevance, publication activity, and the supplied academic identifiers. Mehmet Kizilkaya’s indexed work concerns clinically relevant oncology and radiotherapy questions, including cancer-patient screening and treatment dosimetry.[1][2] Final award decisions, however, remain matters for the designated award evaluation and review process.

Conclusion

Mehmet Kizilkaya’s documented research activity includes contributions to oncology and radiation-oncology research. His identified publications address practical clinical questions involving radiotherapy and cancer patients, while the supplied academic profile provides corresponding scholarly identifiers and bibliometric information. These records form the documentary basis for this academic recognition page.[1][2][3]

References

  1. Kizilkaya, M., Genc, M., Aksu, M. G., Koca, T., & Korcum, A. F. (2022). Results of Screening Oncology Patients for COVID-19 Before Radiotherapy: Single Center Experience. International Journal of Hematology and Oncology, 32(3), 188–190.
    https://doi.org/10.4999/uhod.226389
  2. Koca, T., Aksoy, R. A., Atak, E., Kizilkaya, M., Bilek, Y., Tunçel, N., Sarpün, İ. H., & Korcum, A. F. (2025). Evaluation of the Dosimetric Effects of Bladder and Rectum Filling in Patients with Gynecologic Cancer Receiving Adjuvant Radiotherapy. Turkish Journal of Oncology, 40(1), 11–19.
    https://doi.org/10.5505/tjo.2024.4429
  3. Google Scholar. (n.d.). Mehmet Kizilkaya — Google Scholar profile. Google Scholar.
    https://scholar.google.com/citations?user=LoT5L1kAAAAJ&hl=tr
  4. ORCID. (n.d.). Mehmet Kizilkaya — ORCID record. ORCID.
    https://orcid.org/0000-0003-0266-3919
  5. International Molecular Biologist Awards. (n.d.). Official Award Website.
    https://molecularbiologist.org/

Parastou Tizro | Cancer Biology | Innovative Research Award

Published on by Molecular Biologist

Innovative Research Award

           Researcher Information
Researcher Parastou Tizro
Affiliation City of Hope National Cancer Center
Country United States
Scopus ID 55628206300
Documents 21
Citations 229
h-index 6
Subject Area Cancer Biology
Event International Molecular Biologist Awards
ORCID 0000-0003-1928-8967
Google Scholar yhzdrIwAAAAJ&hl

Parastou Tizro

City of Hope National Cancer Center, United States

Parastou Tizro, whose work in Cancer Biology has contributed to research involving cancer mechanisms, molecular biology, and translational biomedical science. The information summarized in this article is based on publicly available academic records and bibliometric indicators.The Innovative Research Award recognizes researchers who demonstrate originality, scientific rigor, and sustained scholarly contributions within their respective disciplines. This academic profile presents an overview of.[1]

Abstract

Parastou Tizro has developed an academic profile focused on cancer biology through peer-reviewed publications, collaborative research, and contributions to biomedical science. Her research interests include molecular mechanisms of cancer, translational oncology, and related biological processes that support improved scientific understanding of disease. Bibliometric indicators demonstrate an active publication record and growing research visibility.[1][2]

Keywords

Cancer Biology, Molecular Oncology, Biomedical Research, Translational Medicine, Scientific Publications, Research Innovation, Molecular Biology, Cancer Research.

Introduction

Scientific innovation is advanced through rigorous experimentation, collaborative investigation, and the dissemination of reproducible research findings. Academic recognition considers both qualitative scientific contributions and quantitative research indicators, including publication output, citation performance, and scholarly influence across international research communities.[3]

Research Profile

  • Research affiliation with City of Hope National Cancer Center.
  • Primary specialization in Cancer Biology.
  • 21 scholarly publications indexed in Scopus.
  • 229 citations with an h-index of 6.
  • Participation in collaborative biomedical research projects.

Research Contributions

Parastou Tizro has contributed to research investigating molecular pathways associated with cancer biology and translational medicine. Her publications support scientific understanding of cancer-related biological mechanisms and emphasize evidence-based approaches to biomedical research. Collaborative studies have strengthened interdisciplinary knowledge exchange and contributed to peer-reviewed scientific literature.[2][4]

Publications

  • Twenty-one peer-reviewed publications indexed in Scopus.
  • Research addressing cancer biology and molecular biomedical science.
  • Publications cited by researchers within oncology and molecular biology disciplines.

Research Impact

Bibliometric data indicate measurable scientific influence through publication output and citation activity. Citation metrics complement qualitative assessments of originality, methodological quality, and scientific significance used during academic evaluation and recognition processes.[1][5]

Award Suitability

The available publication record, citation metrics, and ongoing scientific contributions suggest that Parastou Tizro demonstrates characteristics commonly considered during academic award evaluations. Participation in the International Molecular Biologist Awards aligns with the objective of recognizing meaningful research achievements while maintaining independent peer-review standards.[3]

Conclusion

Parastou Tizro has established a developing scholarly profile in cancer biology through scientific publications, interdisciplinary collaboration, and measurable research impact. Her academic record reflects continued engagement in biomedical research and contributes to the advancement of knowledge within molecular and cancer biology.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Parastou Tizro, Author ID 55628206300. Scopus.
    https://www.scopus.com/pages/authors/55628206300
  2. Google Scholar. (n.d.). Scholar Profile of Parastou Tizro.
    https://scholar.google.com/citations?user=yhzdrIwAAAAJ&hl=en
  3. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output.
    https://doi.org/10.1073/pnas.0507655102
  4. National Cancer Institute. (n.d.). Cancer Biology Research Resources.
    https://www.cancer.gov/research
  5. International Molecular Biologist Awards. (n.d.). Official Award Website.
    https://molecularbiologist.org/

Ching Siang Tan | Cancer Biology | Research Excellence Award

Published on by Molecular Biologist

 

Research Excellence Award

           Researcher Information
Researcher Ching Siang Tan
Affiliation KPJ Healthcare University
Country Malaysia
Scopus ID 56893025800
Documents 71
Citations 1,356
h-index 18
Subject Area Cancer Biology
Event International Molecular Biologist Awards
ORCID 0000-0002-5069-3314
Google Scholar glKya9IAAAAJ

Ching Siang Tan

KPJ Healthcare University, Malaysia

Ching Siang Tan, whose research activities in Cancer Biology have contributed to scientific understanding through peer-reviewed publications, interdisciplinary collaboration, and internationally indexed research outputs. The information presented follows a neutral, encyclopedic style based on publicly available academic records. The Research Excellence Award recognizes researchers who have demonstrated sustained scholarly productivity, measurable research impact, and meaningful scientific contributions within their respective disciplines. [1]

Abstract

Ching Siang Tan is a Malaysian academic researcher whose work focuses primarily on cancer biology and related biomedical sciences. His research profile includes internationally indexed publications, measurable citation impact, and collaborative scientific activities. With 71 publications, 1,356 citations, and an h-index of 18, his scholarly record reflects continued contributions to cancer research and evidence-based biomedical investigation.[1][2]

Keywords

Cancer Biology, Oncology Research, Biomedical Sciences, Scientific Publications, Citation Analysis, Molecular Medicine, Academic Research, Research Excellence.

Introduction

Cancer biology integrates molecular, cellular, genetic, and clinical research to improve the understanding of cancer initiation, progression, diagnosis, and treatment. Researchers working in this discipline contribute to scientific advancement through laboratory investigations, translational studies, and collaborative research initiatives. Bibliometric indicators such as publication output, citation counts, and the h-index provide objective measures that complement qualitative assessments of scientific achievement.[3]

Research Profile

  • Affiliated with KPJ Healthcare University, Malaysia.
  • Primary research specialization in Cancer Biology.
  • Author of 71 Scopus-indexed scholarly publications.
  • Research has received 1,356 scholarly citations.
  • Current Scopus h-index of 18.

Research Contributions

The scientific work of Ching Siang Tan encompasses investigations in cancer biology, molecular mechanisms of disease, translational biomedical research, and collaborative health sciences. His publications contribute to the growing body of knowledge supporting cancer diagnosis, therapeutic strategies, and biomedical innovation. Research dissemination through peer-reviewed journals has enhanced the accessibility and visibility of his scientific findings within the international research community.[2][4]

Publications

  • 71 peer-reviewed scholarly publications indexed in Scopus.
  • Research articles addressing cancer biology and biomedical sciences.
  • Publications cited by researchers across multiple scientific disciplines.

Research Impact

Citation-based indicators demonstrate sustained scholarly influence and scientific visibility. The combination of publication output, citation performance, and collaborative research activity reflects continuing engagement with internationally recognized research standards and contributes to the advancement of cancer biology.[1][5]

Award Suitability

Based on publicly available bibliometric information, Ching Siang Tan demonstrates characteristics commonly considered during academic award evaluations, including sustained publication activity, measurable citation impact, and continued scientific contributions in cancer biology. Such achievements align with the objectives of international academic recognition programs while remaining subject to independent expert review and evaluation.[3]

Conclusion

The academic profile of Ching Siang Tan reflects sustained engagement in cancer biology research through scholarly publications, international collaboration, and measurable citation performance. His documented research achievements provide evidence of continued contributions to biomedical science and support recognition within academic award programs that value research quality, scientific integrity, and scholarly impact.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Ching Siang Tan, Author ID 56893025800. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56893025800
  2. Google Scholar. (n.d.). Google Scholar Profile of Ching Siang Tan.
    https://scholar.google.com/citations?hl=en&hl=en&user=glKya9IAAAAJ
  3. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output.
    https://doi.org/10.1073/pnas.0507655102
  4. National Cancer Institute. (n.d.). Cancer Biology Research Overview.
    https://www.cancer.gov/research
  5. International Molecular Biologist Awards. (n.d.). Official Award Website.
    https://molecularbiologist.org/

 

Anastasia Stergioula | Cancer Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Anastasia Stergioula | Cancer Biology | Best Researcher Award 

Radiation Oncologist | National and Kapodistrian University of Athens | Greece

Dr. Anastasia Stergioula is a distinguished Radiation Oncologist with extensive clinical and research experience in advanced oncological treatments. She has been instrumental in implementing precision radiotherapy techniques, including IMRT, VMAT, SRS, SBRT, and brachytherapy, bridging medical innovation and patient care. Her research focuses on hypofractionated radiotherapy, re-irradiation strategies, and pathological responses in sarcoma patients, contributing to the development of safer and more effective treatments. Dr. Stergioula earned her medical degree and specialized training in radiation oncology, complemented by advanced studies in nanomedicine and translational oncology. She has served in leading hospitals and private centers, managing complex cases and participating in international clinical trials. Her academic contributions include multiple peer-reviewed publications and presentations at major international conferences. Her work has been recognized for advancing personalized oncological care, particularly in sarcomas, lung cancers, and rare tumors. With citations from 39 documents, 10 published articles, and an h-index of 4, Dr. Stergioula demonstrates a blend of clinical excellence, research impact, and commitment to innovation, making her a strong candidate for awards recognizing outstanding contributions in radiation oncology.

Profile: Scopus | ORCID

Featured Publications

Moutsatsos, A., Cotrutz, C., Stergioula, A., Tuleasca, C., & Pantelis, E. (n.d.). Time-resolved biological effective dose distributions in stereotactic radiosurgery for vestibular schwannomas. Physics in Medicine & Biology.

Hongxi Wu | Cancer Biology | Best Researcher Award

Published on by Molecular Biologist

Mrs. Hongxi Wu | Cancer Biology | Best Researcher Award 

Professor, at China Pharmaceutical University, China.

Dr. Hongxi Wu is a distinguished Research Fellow, Associate Professor, and Graduate Supervisor at the Department of Pharmacology, School of Pharmacy, China Pharmaceutical University. With extensive experience in molecular pharmacology and precision oncology, his research focuses on understanding gene regulatory mechanisms in cancer progression and drug resistance. Dr. Wu has made significant contributions to prostate and liver cancer treatment by identifying novel biomarkers and therapeutic targets. As a leading investigator, he has secured multiple national-level grants and published extensively in high-impact journals. His work bridges fundamental research with clinical applications, aiming to enhance cancer therapy outcomes through innovative drug discovery.

Professional Profile

Scopus

ORCID

Education 🎓

Dr. Wu pursued his academic journey at China Pharmaceutical University. He earned his Bachelor’s degree in Pharmacoeconomics (2007-2011), followed by a Master’s degree in Pharmacology (2011-2014). He continued his Ph.D. research in Pharmacology (2014-2017), investigating molecular mechanisms underlying cancer progression and drug resistance. Dr. Wu then advanced his expertise as a Postdoctoral Research Scientist (2017-2021), further exploring targeted therapies for castration-resistant prostate cancer and hepatocellular carcinoma. His educational background laid a strong foundation for his innovative research in cancer pharmacology.

Research Experience 👩‍🎓

Dr. Wu’s research delves into the molecular mechanisms of gene regulation in cancer, focusing on castration-resistant prostate cancer and liver cancer. He has identified key biomarkers, including AR and ARv7 variants, IRF8, CDK9, and CLKs, which influence prognosis and drug efficacy. His work extends to developing novel combination therapies, such as 2-Methoxyestradiol with Erlotinib and sorafenib with enzalutamide, to enhance treatment effectiveness. Additionally, he investigates innovative anticancer compounds targeting AR, CDK9, and Clk1/2 through chemical biology strategies, aiming to overcome drug resistance in precision oncology.

Research Interests 🎡

Dr. Wu’s primary research interests lie in cancer pharmacology, precision medicine, and targeted therapies. He focuses on understanding tumor progression, metastasis, and drug resistance mechanisms. His work aims to identify novel therapeutic targets and develop personalized treatment strategies for aggressive cancers. Dr. Wu is particularly interested in androgen receptor biology, immune response modulation, and the role of gene expression in chemotherapy resistance. His research integrates molecular biology, pharmacogenomics, and chemical biology to develop innovative cancer treatments.

Awards & Honors 🏆

Dr. Wu has received several prestigious awards recognizing his contributions to cancer research. In 2023, he was honored with the SHIMADZU Young Scholar’s Award for his groundbreaking work in pharmacology. He has also secured multiple research grants, including funding from the National Natural Science Foundation of China, the Natural Science Foundation of Jiangsu Province, and the China Postdoctoral Science Foundation. His outstanding research achievements have earned him national and international recognition, further solidifying his reputation as a leading cancer pharmacologist.

Top Noted Publications 📚

  • Wu H, et al. (2024). Discovery of CLKs inhibitors for the treatment of non-small cell lung cancer.

  • Wu H, et al. (2023). Flavonoid-based CDK9 degraders for prostate cancer treatment.

  • Wu H, et al. (2022). Hepatic IRF8 expression suppresses hepatocellular carcinoma progression and enhances anti-PD1 therapy.

  • Wu H, et al. (2022). A novel AR inhibitor induces protein degradation to overcome enzalutamide resistance in prostate cancer.

  • Wu H, et al. (2020). Loss of IRF8-AR feedback promotes prostate cancer growth and enzalutamide resistance.

Conclusion

Dr. Hongxi Wu is an exceptionally strong candidate for the Best Researcher Award, given his outstanding contributions to oncology pharmacology, impactful publications, and success in securing competitive research grants. While further international collaborations, industry engagement, and leadership in global research networks could further enhance his profile, his achievements in cancer research, particularly in overcoming drug resistance, make him a highly deserving nominee.